ST. LOUIS, MO (Jan. 22, 2018) – Life sciences venture capital firm RiverVest Venture Partners today announced that Sivan Weitzman has joined the firm as Chief Financial Officer. Weitzman brings with her experience as CFO at an Israeli investment firm where, during her 13 years there, assets under management grew from $250 million to $14 […]
ST. LOUIS, MO (Dec. 18, 2018) – Life sciences venture capital firm RiverVest Venture Partners today announced the final closing of RiverVest Venture Fund IV, L.P., reaching $184.4 million in capital commitments in an oversubscribed fundraise. RiverVest Fund IV marks the firm’s fourth dedicated life sciences fund, bringing its total assets under management as of […]
Represents 9th Exit from RiverVest Venture Fund II ST. LOUIS and CLEVELAND (April 3, 2018) – RiverVest Venture Partners today announced portfolio company Securus Medical Group, Inc., has been sold to Boston Scientific Corporation (NYSE: BSX). Boston Scientific has been an investor in Securus since 2016, and the transaction price for the remaining stake not […]
ST. LOUIS, MO (Oct. 25, 2017)—RiverVest Venture Partners announced today that Ronald T. Borchardt, Ph.D. and Jared Rutter, Ph.D. have joined the life science venture capital firm’s Scientific Advisory Board. Comprised of leaders in medical research, RiverVest’s Scientific Advisory Board provides expert guidance to the venture firm as it identifies and invests in promising biopharmaceutical […]
By: David Nicklaus Source: St. Louis Post-Dispatch Date: December 2, 2016 When RiverVest Venture Partners opened its doors in 2000, hopes were high that it would be an important funding source for St. Louis’ nascent biotechnology industry. RiverVest went on to be a highly successful venture capital firm, managing $290 million and demonstrating a knack […]
ST. LOUIS, MO (Nov. 30, 2016) – Life sciences venture capital firm RiverVest Venture Partners today announced the closing of Archer Seed Fund, L.P. at $15 million.
ST. LOUIS, MO (Sept. 16, 2016) – Tioma Therapeutics, Inc., a RiverVest portfolio company developing therapies to treat solid and blood-based cancers, announced it has raised $86 million in Series A venture financing. The Series A financing included early investor RiverVest along with Novo Ventures, GlaxoSmithKline’s corporate venture arm S.R. One, Limited and new investors, Roche […]
By: Bruce V. Bigelow Source: Xconomy Date: April 7, 2016 Xconomy San Diego – RiverVest Venture Partners has stayed mostly under the radar as a small-but-active investor in San Diego life sciences startups for the past 10 years or so. After making investments in San Diego’s Cabrellis Pharmaceuticals and Conforma Therapeutics, the St. Louis, MO-based […]
ST. LOUIS, MO (April 7, 2016) – Life sciences venture capital firm RiverVest Venture Partners announced today that Nancy A. Hong, Ph.D., is joining the firm as managing director. The VC firm also announced that it is opening an office in San Diego where Hong will work with RiverVest Managing Director Niall O’Donnell, Ph.D.
RiverVest Venture Partners Closes on $80 Million Life Sciences Fund ST. LOUIS, MO (May 5, 2015) – Life sciences venture capital firm RiverVest Venture Partners today announced the final closing of RiverVest Venture Fund III, L.P. at $80.2 million.
By: Brian Feldt, Reporter St. Louis Business Journal December 26, 2014 RiverVest Venture Partners, the Clayton-based venture capital firm, has for several years been considered one of the leading investing firms in the nation when it comes to medical technology. This year may be its best campaign yet. RiverVest exited a dozen portfolio companies […]
By: Brian Feldt, St. Louis Business Journal September 8, 2014 Tryton Medical, a company developing stents to treat coronary bifurcation lesions, has raised $20 million in equity from a group of investors that includes St. Louis-based RiverVest Venture Partners and the 3×5 Special Opportunity Fund. Both RiverVest and the 3X5 fund, which is co-managed by […]